Extended Data Fig. 3: Patient outcome analysis and biomarker studies.
(a) Overall survival of patients with complex cytogenetics. (b) Overall survival of patients with TP53 mutation. (c) Overall survival of patients harboring mutations in receptor tyrosine kinase gene (RTK). (d) Level of telaglenastat measured in plasma by LC-MS at indicated timepoints as compared between responders: CR and mCR, n = 7, mean ± SD, and patients with HI and NR n = 9, mean ± SD, ns-no significance. (e) Dynamic of changes in telaglenastat level measured in responders and non-responders at day15 of cycle1, day 1 of cycle 2 and at cycle 4 or later, (CR and mCR, n = 7, HI and NR n = 9, mean ± SD, ns-no significance).
